American Well Corporation (AMWL) Earnings Call Transcript
November 4, 2025
Earnings Call Speaker Segments
Thanks, Operator, and good afternoon, everybody; during Q3, what we delivered stacked up well against the outlook we had shared. We demonstrated consistent advancement in carrying out our strategy, which aims to reach cash flow breakeven by the close of 2026 and, in the end, return to profitable growth. Two primary work streams form the foundation of this strategy. Number one, concentrating on our enterprise-grade, mature, and strongly differentiated new platform so it delivers meaningful value within the market segments we have chosen. Number two, making certain every part of our operations is highly efficient and effective. Each of these pursuits depends greatly on bringing in and embracing fast-changing technologies, chiefly enterprise-grade AI infrastructure. Over the past several years, we have put substantial money into bringing aboard outstanding talent and creating robust governance, compliance, and operational frameworks. We have likewise devoted considerable resources—and keep doing so—toward developing ecosystem interoperability that supports seamless data exchange along with deep integration into the EHRs and clinical systems already in place. Such investments help establish Amwell as a technology-enabled care platform that is highly dependable, secure, and scalable for our customers; we let our customers match our technology with measurable economic value while assisting them in tackling critical difficulties like clinician burnout, staffing shortages, and operational inefficiencies. Beyond that, we put them in position to seize emerging opportunities, among them the integration of algorithm-based health care services, comprehensive care coordination, and new digital therapeutic solutions. Through these integrations, our customers may be able to use predictive AI to cut down on costly interventions and hospitalizations. Our results show that these efforts are starting to bear fruit, and we expect the effect only to speed up from here. Regarding our first work stream in Q3, we started introducing our product focus areas for 2026 to our clients and prospects. We are dedicated to making the new Amwell platform the most effective and valuable hybrid care backbone we have ever given them. Our goal is to assist our customers in lowering care costs, improving clinical outcomes, and delivering the highest member engagement and satisfaction via an exceptional user experience. We aim to accomplish this through the following focus areas: First, we are bringing AI into the core workflow layer; we are responsibly deploying enterprise-grade AI and other technologies to reshape patient intake, personalized dialogue, and navigation, plus clinical program matching and onboarding. Almost 2 decades of telehealth experience, along with access to an incredible data and knowledge repository generated by many millions of digital-first care encounters, support our efforts. Second, we are improving and streamlining how we collaborate with clinical programs from both our own organization and third-party partners. This stronger program integration should help give our customers still more options spanning the care continuum while delivering added value to the partners behind our clinical programs. Additionally, customers can bring the clinical programs they're already using onto their Amwell platform smoothly, with a level of ease we've never offered before. During previous calls, we've mentioned that these outside partners constitute a significant growth opportunity for Amwell, one with high margins that spins like a flywheel. The programs we run ourselves will probably be the earliest to gain from these updates, and they should further strengthen what we provide in urgent care, virtual primary care, comprehensive behavioral health, nutrition, lactation, and beyond. Third, we're putting money into our data and analytics foundation and will stay strongly dedicated to it; our intention is to give customers improved methods for tracking and enhancing financial and clinical results across every program, while giving patients a journey that feels more personalized, straightforward, and pertinent. Given that payers, employers, and health systems are trying to streamline their technology-enabled care approach, what we provide is distinctive and dependable; it lets them achieve their objectives around finances, clinical care, and member engagement, all while keeping complete freedom to swap in and out the clinical programs that suit them best, in the easiest, most scalable, and most repeatable manner. Our second work stream focuses on an unyielding dedication to and emphasis on quality and efficiency. We're making additional upgrades to our platform so that deploying, maintaining, and supporting it becomes simpler still. Tools for self-management and automation that serve our customers illustrate this dedication well. With these tools, clients can accomplish more, more quickly, and at the same time we lower our own deployment expenses. As we take care to pin down exactly what we concentrate on, we're making decisive moves to shed noncore assets. Earlier in the year, we shared news that Amwell Psychiatric Care, or APC, was being sold, and right now we're working on further steps to steer access resources away from assets that aren't core. Worth noting: our plan is to keep fully backing and upkeeping legacy assets that continue delivering value for our customers. Those customers say they take comfort in how stable and reliable our trusted legacy solutions are; our hope is that they'll steadily shift over to our core offering when the timing is right for them. Simultaneously, we took a methodical look at how efficient we are throughout every part of our operations. We identified chances to boost efficiency, among them broad adoption of AI, while adjusting headcount to the right size everywhere. These workforce reductions became feasible via a range of measures, such as thoughtfully moving talent around within the company. Now I want to pull back and examine the macro picture more broadly; during 2025, we keep seeing unmistakable indicators that the market is tilting our way. Consumers are demanding digital health at a quickening pace. Mental health telehealth utilization hit 27.8% in July, per the Epic Research data tracker; and 79% of Gen Z use health technology every month now, per the PwC 2025 Healthcare Consumer Insight survey. Meanwhile, digital clinical programs are proving they deliver genuine outcomes. Studies indicate digital disease management can cut 30-day readmission rates in half. That kind of effectiveness is pulling in substantial investment. According to the AHA Center for Health Innovation, AI start-ups—lots of which might themselves count as clinical programs—took in 60% of every digital health dollar funded during Q1. Even so, payers, employers, and health systems find themselves wrestling with fragmentation. Per Evernorth Insights, employers today juggle between 4 and 9 point solutions on average, and just 22% have faith that such vendors will act in their interest. That fragmentation comes with genuine expense. Take inefficient data exchange: it runs healthcare organizations as much as $20 million each year. Integration therefore has turned into a strategic must. HealthEdge's annual survey shows 62% of health plan leaders naming integrated solutions among their top 2025 priorities. Help is what organizations require for handling technology, engagement, reporting, plus the commercial weight of dealing with numerous vendors—and that gap is precisely where we are positioned to deliver. Given that backdrop, the Amwell platform holds out sorely needed relief, preserving future-ready flexibility alongside the efficiency, effectiveness, and peace of mind that come from a single relationship, a single user experience, and a single data and reporting infrastructure spanning a dynamic, open-ended range of clinical programs and vendors. Never does our distinctive business model compel clients to rely solely on Amwell clinical programs. That keeps our interests aligned and makes us a strong long-term partner for them. Whereas plenty of rivals put their own brands in front of members, we let our customers deliver a white-labeled experience of their own. The Amwell platform within lets them present one unified, customer-branded gateway to every covered program. Last, and crucially, being able to complement automated programs with trusted in-network certified providers at scale makes possible and speeds the safe, effective adoption of these new AI-driven solutions. Our particular architecture helps drive more effective customer acquisition costs and boosts customers' overall brand value and stickiness by tying it to a broad array of helpful services and an exceptional platform experience. Customers highly value and appreciate our capacity to give them a clear view of whole-person and cohort outcomes and to hand them tools for continuously improving results by switching programs and matching them to the right cohorts; out in the market, our strategy keeps resonating in our conversations. Looking ahead, we fully anticipate our competitive advantages growing more visible and compelling as we keep rolling out our new Amwell platform. Our long journey, we believe, is in many respects just getting started, and we are excited for what lies ahead for our loyal and sophisticated supporters, our customers, and our company. With that, I'd like to hand the call to Mark for a review of our financials and our guidance. Mark?
Thank you, Ido, and good afternoon, everyone joining us. During this call, I'll go over several important operating metrics and financial outcomes for Q3, after which I'll share a revision to our guidance covering the rest of this year. For the third quarter, our results came in above what we had expected on both revenue and adjusted EBITDA, which mirrors better subscription retention, higher visit volume across specialty care and virtual primary care, plus substantial cost efficiencies stemming from restructuring efforts that were carried out successfully. The strides made during this quarter confirm that initiatives kicked off earlier in the year are producing lasting financial gains and faster operating leverage. Today, I'll take you through how we performed this quarter, point out the financial effect of these strategic moves, and give you a refreshed outlook for guidance across the balance of 2025. Revenue totaled $56.3 million, marking an 8% decline compared with the same period last year, and this figure incorporates the reduced contribution from Leidos along with the APC divestiture. If we adjust for the APC sale, Q3 revenue would have risen 1.3%. Subscription revenue reached $30.9 million, up 18% versus a year earlier, and accounted for 55% of overall revenue, whereas it was 43% of overall revenue 12 months ago. Roughly 1.1 million visits occurred in the third quarter, a 21% drop from the prior year, though this matched what we had anticipated. Amwell Medical Group, or AMG, visit revenue declined 23% from last year to $21.2 million. However, after adjusting for the APC sale, visits fell 3.5% versus a year earlier. Average revenue per visit came to $71, a figure 14% below what last year's Q3 showed. Yet, adjusting for the APC sale, average revenue per visit climbed 3.5%, propelled by an ongoing mix shift toward higher-priced virtual primary care and specialty care visits. GAAP gross margin grew to 52%, up from 37% a year earlier, due to more software and services revenue producing a stronger margin contribution than the comparable quarter's revenue mix last year, along with the APC divestiture. Operating expenses for the quarter summed to $58.9 million, down 16% from last year, made up of a 6% cut in R&D, a 46% drop in sales and marketing, and a 14% reduction in G&A expenses; we stay committed to optimizing our resources, and we're plainly headed in the right direction, edging nearer to our foundational cost basis. Adjusted EBITDA showed a loss of $12.7 million for the quarter, a favorable comparison against a loss of $31 million a year earlier, demonstrating our sharp focus and the execution of our cost containment initiatives. Regarding cash and liquidity, we recorded a cash burn of roughly $18 million in Q3 and closed the quarter holding approximately $201 million in cash and marketable securities, with 0 debt. So to close out my remarks, I want to walk through our updated guidance. We've got only 2 months left in the year, and at this point we're looking for full year revenue somewhere between $245 million and $248 million, compared with the earlier outlook of $245 million to $250 million. On adjusted EBITDA, we're now calling for negative $45 million to negative $42 million, up from the previous negative $50 million to negative $45 million. For AMG visits, our range hasn't moved — still 1.3 million to 1.35 million visits. This full year outlook bakes in a drop in R&D expenses of more than 10% for this year against 2024, reflecting how we streamlined and finished the majority of our software configuration tied to the build and integration commitments we already had. Meanwhile, we still anticipate that sales and marketing costs will come down more than 25% year-over-year, and that G&A expense will fall at least 20% for the year, as we keep organizing the company around a new, lower cost structure. For Q4, we now expect revenue of $51 million to $54 million and adjusted EBITDA of negative $15 million to negative $12 million. We've achieved meaningful progress in rightsizing the cost structure, and we're working diligently to set Amwell up for longer-term success. There's still a good deal of work ahead of us, but we're staying committed to our objective of producing positive cash flow from operations during 2026. I'd like to thank the whole team for their dedication and passion toward our overarching mission of expanding access to affordable, high-quality health care. Thanks to all of you for your time and attention. At this point I'd like to hand the call back to Ido for his closing remarks. Ido?
Thanks, Mark. A striking shift is underway in the market we serve. AI health care solutions are spreading, both inside Amwell and outside it, and they're producing much better results for patients along with broader access and lower costs; against that backdrop, Amwell's part as an integrated backbone matters more than it ever has. We stand apart in our capacity to combine intelligent automation smoothly with certified, trusted clinicians, which offers a safe and effective route to stronger care outcomes now and in the future. Clients appreciate the track record we've proven in generating quantifiable economic value, all while maintaining compliance and giving crucial help to health care providers who are stretched thin. Enterprise-grade workflow automation lets us improve access as well as operational efficiency. Our mission makes us proud, and we strongly believe it carries greater relevance today than at any point before. Having said that, I'll turn the call over for questions. Operator?
Two things from me. To start, I'd like to revisit the quarter before this one, when a Florida Blues plan win was announced. I'm wondering whether you could share some detail on the way that was won. Did you take it away from a competitor? And do you see similar chances ahead?
Stan, absolutely — this is a significant victory and it makes us very happy. We prevailed against competition, and in this context we're taking out a big rival. What drove it truly reflects all of what I covered during my prepared remarks. My sense is that Florida Blue, in common with numerous other payers, grasped that fragmentation is massive and that AI programs hold massive potential, yet what they require is a single infrastructure beneath their own brand — one that delivers one efficient consumer engagement solution capable of driving care through their own selections of clinical program, perhaps even varying selections across different ASOs or different cohorts, plus one report and one infrastructure. They, in common with plenty of others — current customers and those we speak with while working the pipeline — genuinely raise vendor fatigue and complexity. There's a tami of incredible programs, with some superior to others. A great many of them carry massive potential, yet a great many are risky, and a genuine need exists for one technology-enabled care infrastructure that acts as an integrator and a distributor, so to speak, for members. So every one of those key value points, drawn from our conversations with this highly important customer, in my view, produced this win and signal future demand that will probably expand as more AI-driven programs multiply.
Then I have one more question. About what you said during the prepared remarks regarding possibly divesting more noncore assets. Could you share any detail on which assets those could be? Also, are talks currently underway, or is this largely a hypothetical exercise?
It's quite practical, actually. I'll begin right there. Our main takeaway is that the chance we discussed involving Florida Blue and numerous other parties is extremely exciting. Given that, we chose to concentrate every bit of our effort there, since we see it as the strongest ROI available to Amwell and the finest route to generating value for our clients. We possess quite an extensive roster of older offerings that perform the task, and perform it nicely. Take, for instance, automated hospital programs, inpatient solutions, and similar items. Such offerings are solid, safe, trustworthy, and dependable, and we intend to keep utilizing them, yet we will devote fewer resources — far fewer — toward expanding those market segments, especially when weighed against the unmistakably massive opening I described previously. That genuinely forms a piece of the approach we're putting into action right now.
You brought up AI and rolling it out throughout the company, plus other tech used to help with things like patient intake and navigation. Could you explain how that turns into revenue? Are you charging customers more for it? What does the business model look like when we think about this? And Mark, I realize it's likely still fairly early. How should we frame any sort of guardrails when we look ahead to '26, at least regarding the top line?
Of course, Charles. It goes without saying that AI is touching every single thing we do and every single thing occurring within our ecosystem. The impact is extremely, extremely striking. Let's begin with the product, and let's begin with third-party partners. Take a company such as Sword — their capacity to forecast through AI how likely someone is to undergo surgery in the very near term matters tremendously. Our capacity to direct that patient toward Sword, then capture these savings and relay them back to organizations such as Elevance and others, is tremendously, tremendously valuable. That holds true for other partners too, such as HelloHeart, which can leverage predictive modeling to improve medication adherence management, and there are lots of other examples along these lines. So above all, AI is shaping both Amwell and non-Amwell clinical programs on their own. Beyond that, AI lets us deliver a vastly different consumer experience. It can be extremely personalized. As an individual, you can receive instant attention and enjoy a very straightforward, effortless, attentive, tailored path toward programs that will probably help you. So that's yet another domain where AI brings tremendous value. Turning such value into money — both of these things genuinely boost ROI for our customers and boost traction. So when an excellent experience results in a virtual primary care visit lasting beyond 30 days that saves $500 for our customers, that's extremely beneficial for Amwell. It's extremely beneficial for our customers too. Beyond that, applying AI to data analytics so you can convey information regarding outcomes in a highly coherent manner across various programs for a whole person and a whole cohort lets our customers pick the right programs and hone them as time goes on; it also lets us personalize the consumer experience further and drive more usage — even greater usage and higher NPS going forward; so all these examples within programs essentially boost the value and the traction of our platform. We don't always charge a higher price for our platform directly in order to accomplish that, though we might manage to do so down the road. But far more significantly, as we share in the value of this traction and this traffic, whenever we send someone to Sword, for instance, we receive some rev share from that company, which benefits us and is far better than the alternative customer acquisition cost. So when you step back, all of that spending is genuinely driving additional value for the platform we own. On top of that, as happens at any business, we've recruited some outstanding people out of big tech — folks from Amazon, among other places. And we're reviewing each and every piece of what we do, be it core generation, QA, product management, sales, deployment, support, and everything else along those lines. And just as many other firms are doing, we're putting in a lot of money to get those solutions in place so we can be better, more effective, more efficient. That effort continues and its impact keeps growing. My only suggestion would be this: if you want to put a number on the single most significant financial effect, along with how relevant we'll remain down the road, then I'd point to our capacity to bring a hybrid approach together — pairing certified humans, such as those in our national network, and other options with programs powered by AI — which consequently delivers far stronger financial and clinical results at a far lower cost and with far greater engagement. That is the core of how AI shapes our financial results.
So Mark, how do you want us to frame next year? And if we aren't raising prices on these new capabilities even though we're clearly showing customers better ROI, what's the story on margins? This quarter I believe it came in at 52%. Should we treat that as the baseline for next year? Any perspective you can offer would help.
Sure, Charles. My view is that rolling out the AI features, along with the capabilities we plan to deliver across the year, won't move our margins in any material way. The thing that will most likely drive margin movement between '25 and '26 is the same thing we already experienced in '25, which was our improved capacity to pull additional software revenue into the top line. Obviously, we brought in implementation revenue totaling tens of millions of dollars at very strong margins. Those dollars had an enormous effect on the margin profile, and that explains why we're finishing the year with better margins than we had in '24. I expect '26 will mirror the margin profile from '25.
Possibly one final question, if that's alright. You mentioned selling off some assets that aren't central to the business. APC clearly served as one instance. Are there still plenty of other holdings you'd put in that same noncore category? Also, do you have any sense of when that might happen? Would you want to move on that quite quickly? Or does it depend on getting a favorable price for them?
The second option fits better, Charles; neither of these is currently on the market, and what I'd call them is a pair of specific assets that could be separated from everything else without any loss of attention, without putting any customers in a difficult spot by taking these away; these stand apart, with a particular client mix that we could actually isolate, we could operate them on their own. Still, I believe across '26, we'll aim to, once more, sharpen where we're putting our energy, in the areas Ido laid out during his prepared remarks.
Jenny here, filling in for Jailendra. I wanted to ask about the macro situation, given all the noise out there — tariffs, economic uncertainty. Has there been any effect on your sales pipeline as health systems keep reviewing their IT budgets? I'm just curious how those conversations have gone over the past couple of months. And on a related note, could you discuss your direct exposure to tariffs?
Jenny, basically what we're seeing in the market is that our solution addresses really critical pain points that many customers — including those using the newer offerings — view as mandatory, in the sense that, if you think about it, for a payer, having a reliable, effective solution for hybrid care and technology-enabled care is a tool that sponsors, employers and others demand, and it produces enormous savings. Putting in place effective AI-driven care programs isn't a matter of if — it's truly a matter of how. You have to do it, and that's abundantly clear to our customers. That's extremely dangerous. It's very confusing. It's prone to errors; what we give our customers is the ability to reduce noise by having a single platform embedded in their infrastructure, and far less vendor fatigue, since we handle the heavy lifting of connecting to more and more solutions while keeping it all within one experience and one report; so when we speak with them, that isn't a line item they're likely to skip over even under pressure. When it comes to health systems, we certainly believe that in areas like workflow automation, inpatient solutions, hardware solutions, that sort of thing, there is definitely some pushback at the moment and some caution stemming from the economic impact. That's among the reasons we are shifting resources away from promoting those solutions and toward our core offering. At the same time, if you look at delivery networks implementing value-based care, if you look at their competition for patients, their need to add, say, behavioral health to their core offering, that sort of thing, their ability to extend their reach past catchment areas — all of this directly affects revenues, directly affects their livelihood, and is viewed as essential. So we see that we still have an offering that resonates and remains relevant today. On tariffs, the impact is very minimal. We have a very small business line that still involves some hardware outside the United States; and that, naturally, is affected, but the effect on our performance is negligible; we take pride in building our software as a U.S. company, and therefore — and our businesses are in the U.S. as well; so we don't foresee any meaningful impact — any direct impact when it comes to tariffs. Sure, it may affect the market and the macro just like everyone else, but it isn't specific to Amwell.
Jack Senft here, filling in for Kevin. I'd like to revisit what was said about shifting resources away from the noncore assets. So, to be clear, that isn't baked into this year's guidance, right? And then, as a follow-up, if it isn't — might that accelerate when you reach cash flow breakeven next year? Or could it even significantly bring forward cash flow expectations? If you could share your thoughts on what you're expecting there, that would be great.
Yes. None of the guidance you've seen across 2025, nor the updated guidance we gave for this year's final quarter, accounts for it. The effect it would probably have wouldn't be large enough to alter how we view cash flow breakeven from operations at the close of 2026.
Then, if I could, one more quick question. Your sales and marketing expense came down quite a bit from the prior quarter, I realize. And I realize you're still aiming for reductions of no less than 25% or more for this year. That said, when we consider every individual line item within operating expenses, should we view these as reasonable ongoing levels? Or might there be further efficiencies available to capture in the coming year? I believe you mentioned this briefly, but hearing a bit more detail on it would be helpful.
Yes, of course. Just as you noted, we truly streamlined our spending and brought sales and marketing costs down considerably from one quarter to the next, though clearly, relative to the prior year, the impact is significant. In my view, there remains a sizable chance to remove certain expenses across 2 additional categories, likely G&A. We — one more major category, and probably the largest when measured in absolute dollars, involved our costs and the delivery function. That is the area where we'll probably see gains from deploying AI tools, in both clinical operations and clinical delivery. We'll be able to expand while spending less. And I expect that to become apparent across 2026 and afterward.
You folks mentioned the goal of reaching cash flow breakeven in '26. Plus, with the noncore divestitures currently being discussed, if you needed to order or rank what feeds into that — things like customer renewals, maybe price increases, service mix, or other items I haven't thought of right now, how would that ranking go?
Do you mean how we'd rank those when thinking about our target for cash flow breakeven next year? Or how we rank them simply by top to bottom priority?
Yes. In what order would you tackle those items? Clearly, selling off the noncore assets probably yields a sizable amount there, but I'm just curious how — are there other considerations to keep in mind for hitting that goal?
Yes. Getting rid of those noncore assets will definitely assist in concentrating the business on our core initiatives and would clearly supply some extra dry powder for the balance sheet in addition to our $200 million that we just closed the quarter with; and once again, we carry no debt. So that hands us a bit more leverage. But I think we mainly need to concentrate on client retention, making sure that our platform is delivering and our teams are managing the requests, the growth, the other ROI opportunities that our clients are asking for. So I would probably say retention is #1. And then, naturally, some of the growth initiatives on the product side would then probably be placed as the #2 priority
You brought up Sword as a means to bring on additional partners. Are there certain spaces or subjects where partnering isn't something you'd pursue — where you'd rather keep full ownership instead of connecting through a third party?
What we provide to our customers is the capacity to assist them, under their own brand, in building a single customer acquisition cost gateway tied to whichever programs they select. The reality that we arrive with a ready-made, quite extensive lineup of offerings spanning the entire continuum certainly doesn't hurt. Yet what's even more thrilling is that we're able to add, with great ease, whatever they or their clients wish to put in place. Consequently, provided our customers trust that the offering is logistical, that it's secure, that it complies with various regulations, matters along those lines, we'll happily put it into action as a component of their offering, letting them gain from and track the worth of that deployment.
Thanks to all of you for being here. Your time means a lot to us. It's quite something to witness just how pertinent Amwell proves to be amid such sweeping transformation, and it's thrilling to think about how that will expand further down the road. Thanks once more, and enjoy the rest of your evening.
We appreciate everyone joining us for this call today. That brings the session to a close. Please go ahead and hang up now. Thanks so much.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Well Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to American Well Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.